flow diversion panacea or poison?

Clicks: 190
ID: 189805
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #237 of 263 articles by views in journal of photochemistry and photobiology a: chemistry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 263 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Endovascular therapy is now the treatment of choice for intracranial aneurysms (IAs) for its efficacy and safety profile. the use of FD has recently expanded to cover many types of IAs in various locations. Some institutions even attempt FD as first line treatment for unruptured IAs. The most widely used devices are the Pipeline embolization device (PED), the SILK flow diverter (SFD), the flow redirection endoluminal device (FRED) and Surpass. Many questions were raised regarding the long-term complications, the optimal regimen of dual antiplatelet therapy, and the durability of treatment effect. We reviewed the literature to address these questions as well as other concerns on FD when treating IAs.
Reference Key
ezanaty2014frontiersflow Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Mario eZanaty;Nohra eChalouhi;Stavropoula I. Tjoumakaris;Robert H Rosenwasser;L. Fernando eGonzalez;Pascal eJabbour
Journal journal of photochemistry and photobiology a: chemistry
Year 2014
DOI
10.3389/fneur.2014.00021
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.